Kedrion is a leading biopharmaceutical company that specializes in the development, production and distribution of plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as immune system deficiencies and coagulation disorders.
With a commercial presence in 100 countries, we operate through a fully integrated business model from the collection of plasma in our own centers in the United States to fractionation and production in our manufacturing facilities located in Italy, Hungary and the United States.
First Half Results 2021
Kedrion announces the closing of the first part of the transaction with Liminal
Kedrion signed the SPA on the Second Transaction with Liminal Bioscience
CONTACT & EMAIL ALERTS
Subscribe to the service in order to receive our news